|[August 14, 2014]
Research and Markets: OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/p9s3cc/opportunityanalyze)
has announced the addition of the "OpportunityAnalyzer:
Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 -
Event-Driven Update" report to their offering.
Cystic Fibrosis (CF) is an autosomal recessive disease characterized by
the secretion of thick, sticky mucus which clogs the lungs and leads to
life-threatening lung infections; and obstructs pancreatic enzyme
secretions that are essential for the body to break down and absorb
nutrients. CF patients have a limited number of available treatment
options and significant unmet needs still exist. Opportunities are
significant for new therapies that will improve symptom, change the
course of this disease, as well as increase therapy options.
The introduction of the first disease modifying therapy, Kalydeco
(ivacaftor), by Vertex (News - Alert) in 2012, paved the way for a new class of
therapies known as cystic fibrosis transmembrane conductance regulator
(CFTR) modulators. On June 24, 2014, Vertex announced positive Phase III
clinical trial data for lumacaftor in combination with Kalydeco in
patients with CF who have two copies of the F508del mutation. This novel
combination therapy of CFTR modulators has the potential to treat the
underlying cause of the disease for approximately 50% of all CF patients
and drive rapid growth in the CF market.
Key Questions Answered
What are the pressing unmet needs and remaining opportunities in the
What R&D strategies are drug developers pursuing in the CF
What is the significance of CFTR modulators in the CF market?
What is the clinical and commercial positioning of key pipeline
products in the CF market?
What are the innovative early-stage treatment approaches in the CF
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Current Treatment Options
6 Unmet Needs Assessment and Oppportunity Analysis
7 R&D Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/p9s3cc/opportunityanalyze
[ Back To TMCnet.com's Homepage ]